<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00719550</url>
  </required_header>
  <id_info>
    <org_study_id>20060317</org_study_id>
    <nct_id>NCT00719550</nct_id>
  </id_info>
  <brief_title>AMG 102 Plus ECX for Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Cancer</brief_title>
  <official_title>A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects With Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Efficacy of First-line Treatment With Epirubicin, Cisplatin, and Capecitabine(ECX) Plus AMG 102</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      Study Phase: 1b/2 Indication: Previously untreated subjects with unresectable locally
      advanced or metastatic gastric or esophagogastric junction adenocarcinoma.

      Primary Objective(s):

      Part 1: To identify safe dose levels of AMG 102, up to 15 mg/kg Q3W, to combine with ECX.

      Part 2 (phase 2-double-blind): To estimate with pre-specified precision the effect of the
      addition of AMG 102 to ECX on progression free survival (PFS).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS), as measured by RECIST per local review</measure>
    <time_frame>Subjects coming off study will be contacted by telephone or at routine clinic visits approximately every 3 months until 36 months from date the last subject is randomized into the study.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival, objective response rate, disease control rate, time to response (for responders only), and duration of response (for responders only).</measure>
    <time_frame>Subjects coming off study will be contacted by telephone or at routine clinic visits approximately every 3 months until 36 months from date the last subject is randomized into the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events, significant laboratory value changes form baseline and anti-AMG 102 antibody formation.</measure>
    <time_frame>Subjects coming off study will be contacted by telephone or at routine clinic visits approximately every 3 months until 36 months from date the last subject is randomized into the study.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax and Cmin for AMG 102; Cmax and AUC for epirubicin and cisplatin with or without AMG 102</measure>
    <time_frame>Subjects coming off study will be contacted by telephone or at routine clinic visits approximately every 3 months until 36 months from date the last subject is randomized into the study.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">130</enrollment>
  <condition>Esophagogastric Junction Adenocarcinoma</condition>
  <condition>Gastric Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>Phase 2 Arm C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>AMG 102 placebo plus ECX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Phase 1b dose study with open-labe AMG 102 at 15mg/kg de-escalating to 7.5mg/kg and 5mg/kg if needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AMG 102 at 7.5mg/kg plus ECX</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 2 Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>AMG 102 at 15mg/kg plus ECX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Administered at 625mg/m2 BID orally every day while on study.</description>
    <arm_group_label>Phase 1b</arm_group_label>
    <arm_group_label>Phase 2 Arm A</arm_group_label>
    <arm_group_label>Phase 2 Arm B</arm_group_label>
    <arm_group_label>Phase 2 Arm C</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Administered day 1 of each cycle at 50mg/m2 IV.</description>
    <arm_group_label>Phase 1b</arm_group_label>
    <arm_group_label>Phase 2 Arm A</arm_group_label>
    <arm_group_label>Phase 2 Arm B</arm_group_label>
    <arm_group_label>Phase 2 Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMG 102</intervention_name>
    <description>Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.</description>
    <arm_group_label>Phase 1b</arm_group_label>
    <arm_group_label>Phase 2 Arm A</arm_group_label>
    <arm_group_label>Phase 2 Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Administered day 1 of each cycle at 60mg/m2 IV.</description>
    <arm_group_label>Phase 1b</arm_group_label>
    <arm_group_label>Phase 2 Arm A</arm_group_label>
    <arm_group_label>Phase 2 Arm B</arm_group_label>
    <arm_group_label>Phase 2 Arm C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>AMG 102 placebo will be provided in similar vials as clear, colorless, sterile protein-free solution</description>
    <arm_group_label>Phase 2 Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically confirmed unresectable locally advanced or metastatic gastric or
             esophagogastric junction (EGJ) adenocarcinoma; tumors of the distal esophagus within 5
             cm of the EGJ are eligible

          -  ECOG performance status 0 or 1

          -  Male or female ≥ 18 years of age

        Exclusion Criteria:

          -  Previous systemic therapy (chemotherapy or biologic therapy) for locally advanced or
             metastatic gastric or esophagogastric adenocarcinoma

          -  Less than 6 months have elapsed from completion of prior neoadjuvant or adjuvant
             chemotherapy or chemoradiotherapy.

          -  Subjects with resectable disease or suitable for definitive chemoradiation

          -  Subjects with persistent gastric outlet obstruction, complete dysphagia or feeding
             jejunostomy

          -  Tumors of squamous cell histology

          -  Known central nervous system metastases

          -  Clinically significant upper gastro-intestinal bleeding ≤ 30 days prior to enrollment
             or randomization

          -  Serious or non-healing wound
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <reference>
    <citation>Doshi S, Loh E, Oliner K, Gisleskog PO, Perez Ruixo JJ, Zhang Y, Zhu M.Exposure survival modeling.Journal-001088;</citation>
  </reference>
  <reference>
    <citation>Iveson T, Donehower RC, Davidenko I, Tjulandin S, Deptala A, Harrison M, Nirni S, Lakshmaiah K, Thomas A, Jiang Y, Zhu M, Tang R, Anderson A, Dubey S, Oliner KS, Loh E. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. Lancet Oncol. 2014 Aug;15(9):1007-18. doi: 10.1016/S1470-2045(14)70023-3. Epub 2014 Jun 22.</citation>
    <PMID>24965569</PMID>
  </reference>
  <reference>
    <citation>Oliner K.BM Ph2 Gastric.Journal-004521;</citation>
  </reference>
  <reference>
    <citation>TBD.Ph2 Gastric Exposure Response.Journal-004521;</citation>
  </reference>
  <reference>
    <citation>TBD.Ph2 Gastric PRO.Journal-004521;</citation>
  </reference>
  <reference>
    <citation>Zhu.20060317 ER data.Journal-000728;</citation>
  </reference>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2008</study_first_submitted>
  <study_first_submitted_qc>July 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 21, 2008</study_first_posted>
  <disposition_first_submitted>April 15, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>April 15, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 23, 2013</disposition_first_posted>
  <last_update_submitted>November 13, 2013</last_update_submitted>
  <last_update_submitted_qc>November 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Locally Advanced</keyword>
  <keyword>Metastatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

